What does Actinogen Medical do?
Actinogen (ASX:ACW) is a clinical-stage biopharmaceutical company developing innovative treatments for cancer and other diseases. The company's lead product candidate, Xanamem, is a novel small molecule that targets the DNA damage response pathway. Xanamem is currently in Phase 2 clinical trials for the treatment of advanced pancreatic cancer and in Phase 1 clinical trials for the treatment of advanced solid tumours and acute myeloid leukaemia. Actinogen is also developing a second product candidate, ACT-701, which is a targeted therapy that is currently in preclinical development for the treatment of solid tumours.
Company Snapshot
Is Actinogen Medical a public or private company?
Public
How many people does Actinogen Medical employ?
17
What sector is Actinogen Medical in?
Health Care
Where is the head office for Actinogen Medical?
New South Wales, Australia
What year was Actinogen Medical founded?
1999
Xanamem: A novel small molecule that targets the DNA damage response pathway, currently in Phase 2 clinical trials for the treatment of advanced pancreatic cancer and in Phase 1 clinical trials for the treatment of advanced solid tumours and acute myeloid leukaemia.
ACT-701: A targeted therapy that is currently in preclinical development for the treatment of solid tumours.
Cognitive impairment in early Alzheimer's Disease: A Phase 2b trial is ongoing to evaluate the efficacy and safety of Xanamem in patients with the early stages of Alzheimer's Disease.
Cognitive impairment in Major Depressive Disorder: A Phase 2a trial is currently enrolling patients to evaluate the efficacy and safety of Xanamem in patients with Cognitive Impairment and Depressive Disorder.
Anxiety, sleep & behavioural problems in Fragile X Syndrome: A Phase 2a trial is planned to evaluate the efficacy and safety of Xanamem in patients with Fragile X Syndrome.
Cortisol Hypothesis: Actinogen is developing therapies that target the cortisol hypothesis, which states that dysregulated brain cortisol plays a role in the development and progression of a variety of neurological diseases.
Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.
MD, CEO & Director
Mr. William Edward Souter BCom, IPAA, LLB (Adel)
Chief Financial Officer
Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board
Head of Investor Relations & Corporate Communications
Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.
Head of Clinical Pharmacology & Lead Physician and Depression
Head of Manufacturing
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.
Company Secretary
